What is the Fiscal Year for Arvinas?

Headquarters

New Haven, Connecticut

Industry

Biotechnology Research

Stock Symbol

ARVN

Website

Description

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its PROTAC Discovery Engine to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Based in the biotech hub of New Haven, CT, Arvinas is driven by an industry-leading team dedicated to improving the lives of people living with serious diseases. For more information, visit www.arvinas.com. Community Guidelines: http://bit.ly/ArvinasCG